Project: Game-changing targeted alpha radioimmunotherapy for metastatic prostate cancer
| Acronym | ALPHA (Reference Number: 115458) |
| Duration | 01/11/2021 - 01/05/2024 |
| Project Topic | ALPHA will develop a novel radiopharmaceutical, 211At-PSMA, for targeted alpha radioimmunotherapy (RIT) of metastatic prostate cancer (mPC). ALPHA will also facilitate clinical implementation of the RIT by delivering a validated drug production platform (ATLAS). By the end of the project in 2024, 211At-PSMA combined with a clinically validated ATLAS module for its automated on-site production, will be ready to enter Phase 2 trials. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 15 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Atley Solutions | Partner | Sweden |
| 2 | Telix Innovations S.A. | Coordinator | Belgium |